SSY GROUP(02005): Obtained the drug production registration approval for 0.2g indobufen tablets.
Shi Si Pharmaceutical Group (02005) announced that the group has obtained approval from the Chinese National Medical Products Administration for indomethacin tablets (...
SSY GROUP (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for indobufen tablets (0.2g), which belong to the third category of chemical drugs and are considered to have passed consistency evaluation.
Indobufen tablets are mainly used to treat ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, as well as to prevent thrombosis during hemodialysis.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
